News: Partners Innovation Fund

Syntimmune Closes $50 Million Series B Financing led by Apple Tree Partners

Syntimmune, Inc., a clinical-stage biotechnology company focused on FcRn biology, today announced a $50 million Series B financing led by Apple Tree Partners, which has committed $48 million to the round, with additional participation from other existing investors. The funds from the Series B financing will further advance Syntimmune’s clinical development program.

Get the full story here